The Ontario government announced today that it is expanding eligibility for COVID-19 antiviral treatments and PCR testing to more high-risk individuals.
“I am pleased that we will be able to offer more accessible antiviral treatment options to more people across Ontario,” said Dr. Kieran Moore, Ontario’s Chief Medical Officer of Health. “I ask everyone across Ontario to continue doing their part to keep their communities and loved ones safe by staying up to date on vaccinations and wearing masks.”
Effective immediately, the following higher-risk groups are eligible to be tested and assessed for antiviral treatments, such as Paxlovid, in Ontario:
- Individuals aged 18 and over who are immunocompromised (have an immune system that is weakened by a health condition or medications);
- Individuals aged 70 and over;
- Individuals aged 60 and over with fewer than three vaccine doses; and
- Individuals aged 18 and over with fewer than three vaccine doses and at least one risk condition (e.g., a chronic medical condition)
Anyone who is eligible for an assessment is now also eligible for a PCR test at any testing centre in Ontario.
Beginning April 12, the province is also expanding dispensing locations, for antivirals for eligible people with a prescription, to include participating pharmacies across the province. A list of pharmacies that are dispensing Paxlovid will be available at Ontario.ca/antivirals as of Wednesday, April 13 at 8:00 a.m. The list will be regularly updated as the list of participating pharmacies expands.
Treatment for antivirals must be started within five days of symptoms in most cases. Individuals who are part of higher risk groups and who have COVID-19 symptoms should immediately seek testing and care, by contacting their health care provider or visiting a clinical assessment centre. Individuals can contact Telehealth Ontario at 1-866-797-0000 for more information about where to find a clinical assessment centre or to determine if they are at higher risk.
Individuals can access Ontario’s antiviral screener tool to help determine if they are at higher risk and should be assessed for treatment. A positive rapid antigen test, PCR or rapid molecular test is required as part of the assessment for antiviral treatment. Rapid antigen tests remain available for pick up at no charge from over 3,000 retail locations in the province. Clinical assessment centres continue to be available to assess and test patients as well as to prescribe and dispense antivirals.
The province is also working with health system partners and health care providers to also prioritize groups that may be at increased risk due to other health-related factors and barriers to health care including First Nation, Inuit and Métis individuals, Black individuals and members of other racialized communities. Health care providers may also determine if antiviral treatment is appropriate for patients based on individual circumstances even if they do not belong to one of the groups listed.
Ontario is able to expand access to antiviral treatments as a regular supply of Paxlovid is expected throughout the rest of the year. Paxlovid, manufactured by Pfizer, was approved by Health Canada on January 17, 2022.
Don’t miss out on Doppler!
Sign up here to receive our email digest with links to our most recent stories.
Local news in your inbox three times per week!
Click here to support local news
Brenda Begg says
This is wonderful news!
Ruby Truax says
Please be aware that Paxlovid was granted emergency use authorization by the FDA in December, and when Pfizer applied for the authorization they presented data from a clinical trial conducted in 2021. Paxlovid is still being studied, so all of the risks and side effects are not yet known.
There is a long list of medications Paxlovid may interact with, including drugs to treat heart arrhythmias, anticoagulants, cholesterol-lowering medications, and organ anti-rejection drugs. People with kidney disease should not take Paxlovid. There has been no trial using Paxlovid in pregnant or breastfeeding women.
Also, in their latest safety bulletin, ISMP Canada reported that some of the drug interactions can lead to life-threatening situations, and that while many pharmacies rely on drug interaction software to identify these interactions, not all software has been updated to detect interactions involving Paxlovid.
Please be aware.
Brenda Begg says
Ruby Truax: Thank you for sharing this information. I didn’t know anything about Paxlovid other than it’s an antiviral treatment option.